Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab With or Without Targeted Peripheral Laser Photocoagulation for Macular Edema Due to CRVO
NCT04444492Phase 3Active, not recruiting
- Sponsor
- Justus Liebig University Giessen
- Start
- Aug 2020
- Primary completion
- Nov 2027
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of ranibizumab in macular edema, central retinal vein occlusion (CRVO), sponsored by Justus Liebig University Giessen. Started Aug 2020; status: active, not recruiting.
02
Drugs
ranibizumab
03
Conditions
macular edemacentral retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on NCT04444492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04444492.